ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1361

Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis

Harneet Ghumman1, Asra Firdous1, Megan Quinlan-Waters1, Amy Cassedy2, Angela Merritt1, Hermine Brunner3, Alexei Grom1, Daniel Lovell1 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cleveland, OH, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, dermatomyositis, Myopathies, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis and multi-organ involvement. Treatment with systemic immunosuppression is needed. Evidence is limited on the factors associated with disease remission off of medication.

The aims of this study are to describe the demographic, clinical, laboratory, imaging and histological factors in our JDM cohort, and to identify variables associated with medication-free remission.

Methods: This is a retrospective study of a convenience sample of children diagnosed with JDM at ≤18 years of age by a pediatric rheumatologist, with a minimum clinical follow-up of 2 years. Medication-free remission was defined as inactive JDM off all systemic medications for at least 6 months. Medical records were reviewed. We compared the following variables in children who achieved remission to those who did not: demographics, clinical features, muscle enzymes, ANA, myositis-specific auto-antibodies, Childhood Myositis Assessment Scale (CMAS; to assess disease activity), Physician Global Assessment Scores, and Parent/Patient Global Assessment Scores. Group differences were tested using Fisher’s Exact tests and Wilcoxon Rank Sum tests. A p< 0.05 was considered statistically significant. Analysis was conducted using SAS 9.3©.

Results: Of 36 participants, 29 (80.5%) achieved medication-free remission while 7 (19.4%) were still on medication at last follow-up. Overall, most were non-Hispanic White (83%), females (69%), had a median age of JDM onset 4 years (range 3-6.5), and diagnosed in the fall (11, 30.6%) and summer (11, 30.5%). Those who achieved remission required treatment for 37 (interquartile [IQR] 27-47) months before discontinuation. Comparing children who achieved medication-free remission to those who did not, median age at JDM onset (4 [IQR 3-6] vs 6 [4-10] years), JDM diagnosis (5 [3-6] v. 8 [4-11] years), and time to treatment initiation (3 [0-14] vs 14 [2-27] days) was not statistically significant. However, more males (71% [n=5] vs. 21% [6], p=0.017) and African Americans (43% [3] vs. 7% [2], p=0.045) did not achieve remission. Further, most of these patients were diagnosed in the fall (43% [3] vs. 28% [8], p=0.034). Both groups had similar presentation of rash, muscle weakness, elevated muscle enzyme levels, ANA positivity, abnormal muscle and skin biopsy, and MRI findings (in those who had them done). 92% were treated with glucocorticoids. Methotrexate (86%) was the most commonly prescribed DMARD. There were no differences in systemic medications given over the disease course between both groups (Table 2). At last follow up, children who did not achieve remission had worse physician global assessment scores (0 [0-0.5] vs 1.5 [0-2.5], p=0.012), but similar CMAS, and patient/parent scores (Table 3).

Conclusion: The majority of patients achieved medication-free remission. Similar to other JDM cohorts, most were female and young at diagnosis. Sex and race may be important factors as more children who were male or African American did not achieve medication-free remission. Further studies are needed to confirm these findings.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: H. Ghumman, None; A. Firdous, None; M. Quinlan-Waters, None; A. Cassedy, None; A. Merritt, None; H. Brunner, Cincinnati Children's Hospital, Pfizer, GlaxoSmithKlein(GSK), AbbVie/Abbott, AstraZeneca, Medimmune, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, EMD Serono, Idorsia, Cerecor, Janssen, Roche, Merck/MSD, Novartis, R-Harm, Sanofi; A. Grom, Sobi, Novartis; D. Lovell, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKlein(GSK), Novartis, UCB, Bristol-Myers Squibb(BMS), Pfizer, Janssen, NIH/NIAMS, NIH/NICHD, Roche; S. Angeles-Han, None.

To cite this abstract in AMA style:

Ghumman H, Firdous A, Quinlan-Waters M, Cassedy A, Merritt A, Brunner H, Grom A, Lovell D, Angeles-Han S. Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-medication-free-remission-in-juvenile-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-medication-free-remission-in-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology